Providers

Latest News

Venetoclax showed “remarkable efficacy” in older patients, with an response rate of 91% in the octogenarian group—similar to what has been reported in younger cohorts. | Image credit: sovova - stock.adobe.com
Venetoclax Effective in Older Patients With CLL

June 20th 2025

Venetoclax demonstrated impressive efficacy in octogenarians with CLL, although treatment management posed some challenges.

Cleveland Clinic Main Campus | Image: Cleveland Clinic
Optimizing Advanced Cancer Therapies and Addressing Logistical, Financial Challenges

June 19th 2025

Westin Forrestal Princeton | Image: Westin
Value-Based Care Calls for Putting Novel Therapies Closer to Patients

June 19th 2025

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com
Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

June 19th 2025

Democratic Doctors Caucus June 11 Press Conference
Democratic Doctors Caucus Reaffirms EMTALA Amid Trump's CMS Policy Reversal on Abortion Care

June 18th 2025

<1
...
110111112113114

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo